Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oliveri, R. L.
Right arrow Articles by Quattrone, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oliveri, R. L.
Right arrow Articles by Quattrone, A.
Neurology 1999;53:1425
© 1999 American Academy of Neurology
Articles

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD

R. L. Oliveri, MD, MSc, G. Annesi, PhD, M. Zappia, MD, D. Civitelli, PhD, R. Montesanti, MD, D. Branca, MD, G. Nicoletti, MD, P. Spadafora, PhD, A. A. Pasqua, PhD, R. Cittadella, PhD, V. Andreoli, PhD, A. Gambardella, MD, U. Aguglia, MD and A. Quattrone, MD

From the Institute of Neurology (Drs. Oliveri, Zappia, Montesanti, Gambardella, Aguglia, and Quattrone), Department of Medical Sciences, University of Catanzaro; and the Institute of Experimental Medicine and Biotechnology (Drs. Oliveri, Annesi, Civitelli, Branca, Nicoletti, Spadafora, Pasqua, Cittadella, Andreoli, Gambardella, and Quattrone), National Research Council, Mangone (CS), Italy.

Address correspondence and reprint requests to Prof. Aldo Quattrone, Clinica Neurologica, Policlinico Universitario MaterDomini, Via T. Campanella, 88100 Catanzaro, Italy; e-mail: quattro{at}imseb.cs.cnr.it

OBJECTIVE: To investigate whether polymorphisms in the genes for dopamine receptors D1 and D2 are associated with the risk of developing peak-dose dyskinesias in PD.

BACKGROUND: Peak-dose dyskinesias are the most common side effects of levodopa therapy for PD. The identified predictors may only partially account for the risk of developing peak-dose dyskinesias because a substantial proportion of patients never develop peak-dose dyskinesias. Genetic factors could play a role in determining the occurrence of peak-dose dyskinesias.

METHODS: A case-control study of 136 subjects with sporadic PD and 224 population control subjects. We studied three polymorphisms involving the dopamine receptor D1 gene and one intronic short tandem repeat polymorphism of the dopamine receptor D2 gene.

RESULTS: The polymorphisms of the dopamine receptor D1 gene were not associated with the risk of developing PD or peak-dose dyskinesias. The 15 allele of the polymorphism of the dopamine receptor D2 gene was more frequent in parkinsonian subjects than in control subjects. More important, the frequency of both the 13 allele and the 14 allele of the dopamine receptor D2 gene polymorphism was higher in nondyskinetic than in the dyskinetic PD subjects. The risk reduction of developing peak-dose dyskinesias for PD subjects carrying at least 1 of the 13 or 14 alleles was 72% with respect to the PD subjects who did not carry these alleles.

CONCLUSIONS: Certain alleles of the short tandem repeat polymorphism of the dopamine receptor D2 gene reduce the risk of developing peak-dose dyskinesias and could contribute to varying susceptibility to develop peak-dose dyskinesias during levodopa therapy.

Key words: Dopamine D2 receptor gene—Gene polymorphism—Dyskinesias.




This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
B. Thanvi, N. Lo, and T. Robinson
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Postgrad. Med. J., June 1, 2007; 83(980): 384 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. Zappia, G. Annesi, G. Nicoletti, G. Arabia, F. Annesi, D. Messina, P. Pugliese, P. Spadafora, P. Tarantino, S. Carrideo, et al.
Sex Differences in Clinical and Genetic Determinants of Levodopa Peak-Dose Dyskinesias in Parkinson Disease: An Exploratory Study
Arch Neurol, April 1, 2005; 62(4): 601 - 605.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Kaiser, A. Hofer, A. Grapengiesser, T. Gasser, A. Kupsch, I. Roots, and J. Brockmoller
L -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism
Neurology, June 10, 2003; 60(11): 1750 - 1755.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C Marras and A E Lang
Measuring motor complications in clinical trials for early Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, February 1, 2003; 74(2): 143 - 146.
[Full Text] [PDF]

Home page
 NeurologyHome page
M. Zappia, G. Annesi, A. Quattrone, J. Wang, Z.-L. Liu, and B. Chen
Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD
Neurology, March 12, 2002; 58(5): 837 - 838.
[Full Text] [PDF]

Home page
 NeurologyHome page
J. Jankovic
Levodopa strengths and weaknesses
Neurology, February 1, 2002; 58(90001): S19 - 32.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P. Costa-Mallen, L. G Costa, T. Smith-Weller, G. M Franklin, P. D Swanson, and H. Checkoway
Genetic polymorphism of dopamine D2 receptors in Parkinson's disease and interactions with cigarette smoking and MAO-B intron 13 polymorphism
J. Neurol. Neurosurg. Psychiatry, October 1, 2000; 69(4): 535 - 537.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.